- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05623800
HIV Education Kit for Adolescents (Pencegahan HIV di Kalangan Remaja), PREM-Kit (PREM-Kit)
The goal of this community trial is to provide HIV education based on the newly developed HIV education kit (PREM-Kit) and evaluate the knowledge, attitude and practices related to HIV prevention among the late adolescents (aged 18 to 19 years old) in Malaysia. The main question it aims to answer is does the PREM-Kit improve the knowledge, attitude and practices related to HIV prevention among the adolescent?
Participants will be asked to:
- answer a questionnaire as a baseline screening to determine their knowledge, attitude and practices related to HIV prevention.
- Using PREM-Kit, they will participate in a series of health education sessions. There will be three sessions in total which will be delivered two weekly apart. Each of the sessions will take approximately 20 minutes duration.
- Following the last session (third session), participants will have to answer the same questionnaire ; once immediately after the last session, once at 3-months post-intervention, and lastly, at 4-months post-intervention.
Researchers will compare participants who received the existing Basic Science and Biology module to see if there is any improvement in the knowledge, attitude and practices related to HIV prevention.
Study Overview
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Wan Nur Syamimi N Wan Mohamad Darani
- Phone Number: +60126370747
- Email: wnsyamimi3007@gmail.com
Study Locations
-
-
Perak
-
Tapah, Perak, Malaysia, 35400
- Universiti Teknologi MARA (UiTM Campus Tapah)
-
-
Pulau Pinang
-
Kepala Batas, Pulau Pinang, Malaysia, 13200
- Universiti Teknologi MARA (Bertam Campus)
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- late adolescents aged 18 - 19 years
- student who attends Health Science Diploma course in the year 2023
- Malaysian citizen
Exclusion Criteria:
- student who refused to participate in the study
- student who is absent on the first session of the intervention
- student who does not understand the Malay language
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Control group
|
|
Experimental: PREM-Kit group
|
The PREM-Kit, which was created based on the Information-Motivation-Behavioral Skills model, is used in a series of HIV education sessions as part of the intervention.
Over the course of three sessions, there will be a total of six weeks (one session for every two weeks).
Three sub-modules, namely HIV facts and information, motivation for HIV preventive behavior, and behavioral skills for HIV prevention, will be emphasized in each session to the participants via flip chart and health educational videos.
Additionally, participants will receive a QR code that gives them access to the PREM-Kit's e-flip chart, which they can see at a later time.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in knowledge score related to HIV prevention
Time Frame: t1:Measurement of knowledge score before intervention. t2:Measurement of knowledge score immediately post-intervention. t3:Measurement of knowledge score at 3-months post-intervention. t4:Measurement of knowledge score at 4-months post-intervention.
|
Knowledge score will be determined by using 15 questions related to HIV/AIDS transmission and prevention.
The participants will be asked to respond on the individual statement using "Yes" or "No" or "I do not know" response.
Each correct answer will be credited with 1 point, whereas wrong answers and ''I don't know'' answers will be assigned 0 points.
The sum calculated to determine a total score for this scale.
The possible range of total score is 0 to 15, where higher score indicates higher level of knowledge.
|
t1:Measurement of knowledge score before intervention. t2:Measurement of knowledge score immediately post-intervention. t3:Measurement of knowledge score at 3-months post-intervention. t4:Measurement of knowledge score at 4-months post-intervention.
|
Change in attitude score related to HIV prevention
Time Frame: t1:Measurement of attitude score before intervention. t2:Measurement of attitude score immediately post-intervention. t3:Measurement of attitude score at 3-months post-intervention. t4:Measurement of attitude score at 4-months post-intervention.
|
To assess the attitude score, eight items are used to assess the participants' attitude toward HIV/AIDS prevention.
It consists of 5-point Likert scale (strongly agree, agree, undecided, disagree and strongly disagree).
The scale given to the answers which is positive or agreeable is in the order of 5, 4, 3, 2, and 1.
The scale given to the negative answers is in the reverse order.
The possible range of the total score is 8 to 40, where higher score indicates higher positive attitude related to HIV prevention.
|
t1:Measurement of attitude score before intervention. t2:Measurement of attitude score immediately post-intervention. t3:Measurement of attitude score at 3-months post-intervention. t4:Measurement of attitude score at 4-months post-intervention.
|
Change in practice score related to HIV prevention
Time Frame: t1:Measurement of practice score before intervention. t2:Measurement of practice score immediately post-intervention. t3:Measurement of practice score at 3-months post-intervention. t4:Measurement of practice score at 4-months post-intervention.
|
Practice score will be assessed by six questions.
All practice items are measured by "Yes", "No" and "I do not know" response.
For questions such as (i) Do you watch any form of pornography?, (ii) Do you smoke?, (iii) Have you ever drink alcohol?, (iv) Have you ever tried any narcotic drugs?, and (v) Have you ever had sexual intercourse?, the "Yes" and "I do not know" responses will be scored as 0 point and "No" response will be scored as 1.
On the other hand, the question of (vi) Have you ever talked about AIDS or HIV infection with your parents or other adults in your family?, "Yes" response will score 1 point, whereas, "No" and "I do not know" response will score 0. The possible range of total score of this practice measure is between 0 to 6, where higher score is indicative for more good practices related to HIV prevention.
|
t1:Measurement of practice score before intervention. t2:Measurement of practice score immediately post-intervention. t3:Measurement of practice score at 3-months post-intervention. t4:Measurement of practice score at 4-months post-intervention.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Wan Nur Syamimi N Wan Mohamad Darani
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immune System Diseases
- Slow Virus Diseases
- Urogenital Diseases
- Genital Diseases
- HIV Infections
- Acquired Immunodeficiency Syndrome
- Immunologic Deficiency Syndromes
Other Study ID Numbers
- REC/05/2022 (ST/MR/85)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Human Immunodeficiency Virus
-
Merck Sharp & Dohme LLCWithdrawnHIV-1 | Immunodeficiency Virus Type 1, Human | Human Immunodeficiency Virus Type 1 | Human Immunodeficiency Virus 1
-
MacroGenicsNational Institute of Allergy and Infectious Diseases (NIAID); National Institutes... and other collaboratorsActive, not recruitingHuman Immunodeficiency Virus I Infection | Immunodeficiency Virus Type 1, Human | Human Immunodeficiency Virus Type 1United States
-
National Institute of Allergy and Infectious Diseases...CompletedHuman Immunodeficiency Virus (HIV) | Human Immunodeficiency Virus PreventionUnited States
-
EMD SeronoCompletedHuman Immunodeficiency Virus Infections | Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome (HARS)
-
EMD SeronoCompletedHuman Immunodeficiency Virus Infections | Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome (HARS)
-
ViiV HealthcareGlaxoSmithKlineCompletedInfection, Human Immunodeficiency Virus | Infections, Human Immunodeficiency Virus and HerpesviridaeUnited States
-
bioLytical LaboratoriesNot yet recruitingHuman Immunodeficiency Virus I Infection | Human Immunodeficiency Virus II Infection
-
Janssen R&D IrelandCompletedHuman Immunodeficiency Virus Type 1United States, France, United Kingdom, Belgium, Spain, Switzerland, Sweden, Canada, Puerto Rico, Poland
-
ViiV HealthcareGlaxoSmithKlineCompletedInfection, Human Immunodeficiency VirusUnited States
-
ViiV HealthcareGlaxoSmithKlineTerminatedInfection, Human Immunodeficiency VirusSpain, France, Germany
Clinical Trials on PREM-Kit
-
Hospital General Universitario Gregorio MarañonUnknownPreterm Infants | Parenting | Training SupportSpain
-
Shalvata Mental Health CenterUniversity of HaifaUnknownSchizophrenia | Rehabilitation | Severe Mental IllnessIsrael
-
University of MiamiRecruitingHypoplastic Left Heart SyndromeUnited States
-
University of MichiganCompleted
-
IdentigeneCRI Lifetree Clinical ResearchUnknown
-
Merck KGaA, Darmstadt, GermanyCompleted
-
South Dakota State UniversityUniversity of Missouri-Columbia; Ohio State University; Michigan State University and other collaboratorsCompletedFood Security | Nutritive Value
-
Firalis SAActive, not recruitingAMI PatientsFrance, Korea, Republic of
-
Imagine InstituteTerminated
-
IDinsightMinistry of Health, Zambia; Clinton Health Access Initiative Inc.; UNICEF; Minister...Completed